CTSI awards 10 new Translational Pilot Studies grants for 2026

Pictured, in alphabetical order, are the principal investigators and co-investigators for projects awarded 2026 CTSI Translational Pilot Studies Program funding.

Published January 7, 2026

The University at Buffalo’s Clinical and Translational Science Institute (CTSI) Translational Pilot Studies Program annually provides seed money to investigators to assist them in developing promising technologies and therapeutics from the conceptual stage to clinical studies. For 2026, 10 new grants — involving 38 principal investigators and co-investigators — have been awarded to support studies addressing complex and serious public health issues. 

These include dental implant failure, infections caused by antibiotic resistant bacteria, diabetes and obesity treatment, opioid use disorder, pancreatic cancer, and periodontitis. The studies incorporate cutting-edge technology, including artificial intelligence, metagenomic sequencing, and novel wearable technology.

“The projects awarded pilot studies grants for 2026 address important clinical and translational science questions,” says CTSI Director Sanjay Sethi, MD, SUNY Distinguished Professor, Senior Associate Dean for Clinical and Translational Research, Jacobs School of Medicine and Biomedical Sciences. “These innovative projects will contribute to our efforts to enhance health and healthcare in Western New York and beyond. Congratulations to the investigators involved in this group of studies.”

This year’s awarded projects are summarized below. In addition, four studies featuring translational science elements are noted. 

Targeting Tumor-intrinsic and CAF-dependent MET-Signaling to Overcome KRAS-inhibitor Resistance
Clonal and Spatial Immune Mapping in Human Periodontitis
Improving Geriatric Patient Safety at Hospital Discharge Using Patient-friendly Artificial Intelligence-modified Discharge Instructions (AIM-DI)
Dehydration and GLP-1-based Medications
Defining Potential Determinants Targets for Peri-implant Disease Surveillance
An Ex Vivo Infection Model to Explore Bacteriophage, Bacteria, and Mammalian Interactions
Progressive Foundation Model Adaptation for Robust Multi-institutional Alzheimer’s Disease MRI Detection
Integrated Optimization of Polypharmacologic Compounds for the Treatment of Opioid Use Disorder
Mechanisms of Cancer-related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
Wearable Multimodal Ultrasound and Photoacoustic Patch for Monitoring Hypoxemia in the Fetal Brain

This program is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UM1TR005296 to the University at Buffalo, as well as: UB’s Office of the Provost, Office of the Vice President for Research and Economic Development, and Office of the Vice President for Health Sciences; Roswell Park Comprehensive Cancer Center; and the deans of UB’s Jacobs School of Medicine and Biomedical Sciences, School of Dental Medicine, School of Pharmacy and Pharmaceutical Sciences, School of Engineering and Applied Sciences, School of Public Health and Health Professions, and School of Nursing.